Genmab A/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that the Phase 3 EPCORE DLBCL-1 study evaluating epcoritamab monotherapy versus investigator’s choice chemoimmunotherapy failed to meet its primary endpoint in the United States. The trial, which compared the T-cell engaging bispecific antibody against standard regimens in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplantation, did not demonstrate statistically significant improvement in overall survival (OS)—the sole primary endpoint for the U.S. regulatory region.
Clinical Trial Overview
| Item | Detail |
|---|---|
| Study Name | EPCORE DLBCL-1 |
| Phase | Phase 3, global, open-label, multi-center, randomized |
| Patient Population | Adults with R/R DLBCL ineligible for autologous stem cell transplantation |
| Intervention | Epcoritamab monotherapy (CD3xCD20 bispecific antibody) |
| Comparator | Investigator’s choice: R-GemOx (rituximab + gemcitabine + oxaliplatin) or BR (bendamustine + rituximab) |
| U.S. Primary Endpoint | Overall Survival (OS) |
| Trial Outcome (U.S.) | Did not meet primary endpoint – no statistically significant OS improvement |
Drug Profile & Current Status
- Epcoritamab: T-cell engaging bispecific antibody targeting CD3 (T-cell receptor) and CD20 (B-cell marker), designed to redirect T-cells to eliminate malignant B-cells
- Current Approval: Granted under FDA’s accelerated approval pathway for adult patients with R/R DLBCL, not otherwise specified (NOS), including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma, after two or more lines of systemic therapy
- Mechanism Advantage: Subcutaneous administration offers convenience over intravenous therapies, with potential for outpatient treatment
- Global Development: Part of Genmab and AbbVie’s broader collaboration to develop epcoritamab across multiple B-cell malignancies
Regional Endpoint Differences
- U.S. Regulatory Framework: FDA required overall survival as the confirmatory endpoint for converting accelerated approval to full approval
- Other Regions: Trial included prespecified primary endpoints that differ by region, potentially including progression-free survival (PFS) or other surrogate endpoints acceptable to non-U.S. regulatory authorities
- Statistical Implications: Failure to demonstrate OS benefit in the U.S. population may impact the drug’s commercial trajectory in the world’s largest pharmaceutical market
- Accelerated Approval Risk: Results raise questions about potential accelerated approval withdrawal if confirmatory evidence fails to verify clinical benefit
Market Impact & Strategic Implications
- Commercial Exposure: DLBCL represents one of the most common forms of non-Hodgkin lymphoma, with approximately 25,000 new cases annually in the U.S. alone
- Competitive Landscape: Epcoritamab competes with other CD20-targeting therapies, CAR-T products (Yescarta, Breyanzi), and emerging bispecific antibodies (mosunetuzumab, glofitamab)
- Partnership Dynamics: Genmab retains U.S. commercial rights while AbbVie holds ex-U.S. rights, creating asymmetric financial impact from the trial outcome
- Investment Reaction: Genmab shares are expected to face pressure following the announcement, while AbbVie’s diversified portfolio may provide insulation from single-product setbacks
Forward Path Considerations
- Regulatory Engagement: Companies will likely engage with FDA to discuss potential pathways forward, including analysis of secondary endpoints or subgroup populations
- Global Strategy: Success in non-U.S. regions could still support international commercial expansion, depending on regional endpoint results
- Pipeline Diversification: Both companies maintain robust oncology pipelines, with epcoritamab being evaluated in earlier lines of therapy and combination regimens
- Clinical Practice Impact: Despite OS results, clinicians may continue using epcoritamab based on response rates, safety profile, and patient convenience factors
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial outcomes, regulatory pathways, and commercial expectations. Actual results may differ due to regulatory decisions, competitive dynamics, and evolving clinical practice patterns.-Fineline Info & Tech
